9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

Bipolar Disorder Clinical Trial

Official title:

A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs. Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501006 (Secondary Title: ARES)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00143182
• Other study ID #: P07007
• Secondary ID: A7501006
• Status: Completed
• Phase: Phase 3
• Start date: January 7, 2005
• Est. completion date: June 28, 2006

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes). Asenapine is an investigational medication for the treatment of manic or mixed episodes of bipolar disorder. Patients who completed the 3 week trial (A7601004 or A7501005) continued on the same treatment that they received in the short term study: asenapine or olanzapine (a medication already approved for the treatment of bipolar mania) for 9 additional weeks. The short term studies (A7501004 and A7501005) were not unblinded until the 9 week extension study was unblinded. Patients treated with placebo in the 3 week short term study were crossed over and treated with Asenapine in the 9 week extension study. Patients who complete the 9 week extension study were eligible to continue in another extension (A7501007) study for an additional 40 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 504
• Est. completion date: June 28, 2006
• Est. primary completion date: June 28, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have completed an asenapine 3-week study for the treatment of an acute manic or mixed episode and not had a major protocol violation.in the short term study (A7501004 or A7501005) that they completed.

Exclusion Criteria:

• Patients with unstable medical conditions or clinically significant laboratory abnormalities.

Related Conditions & MeSH terms

• Bipolar Disorder

Intervention

Drug:
• Asenapine
Asenapine , 9 weeks
• Olanzapine
Olanzapine, 9 weeks

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Organon and Co	Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale		The YMRS is administered at weeks 1, 3, 6 and 9 or endpoint.
Secondary	Changes on the Clinical Global Impression Scale in which Mania, Depression and Overall Status were assessed.		The Global assessment at Weeks 1,3, 6 and 9 or endpoint
Secondary	Improvement in symptoms of depression (measured by the Montgomery Asberg Rating Scale of Depression - the MADRS), psychoses (Positive and Negative Symptoms Scale -- the PANSS) and suicidality (ISST-- The InsterSept Suicidality Scale)		PANSS and MADRS administered at weeks 1,3,6 and 9 or endpoint; ISST administered at Weeks 1 and 6.
Secondary	Changes in the Quality of Life and the TSQM and changes in Readiness to Discharge Questionaire [RDQ]. The investigator's judgment was the basis for a decision to discharge the subject from the hospital.		Quality of Life measures were administered at week 9 or endpoint and the RDQ was administered to inpatients at week 1, 3, 6 and 9.or endpoint.
Secondary	Physical exams and electrocardiograms findings; changes in vital signs, weight and abdominal girth and hematology and urinalysis.		Physical exams and ECGs at Week 9 or endpoint; Vital signs, weight and abdominal girth at weeks 1, 3, 6 and 9 or endpoint; hematological parameters assessed at weeks 1 and 9 or endpoint; urinalysis was done at Week 9 or endpoint.
Secondary	Cognition -- the cognitive battery was the same battery that the subject had in the short term study in which they participated -- CNS Vital Signs for A7501005 and Cogstate for A7501004.		The cognitive battery was done at Week 9 or endpoint
Secondary	Extrapyramidal symptoms were assessed using the AIMS (Involuntary Movement Scale); the BARS (Barnes Akathisia Rating Scale) and the SARS (Simpson Angus Rating Scale).		Extrapyramidal symptoms were assessed at Week 9 or endpoint.
Secondary	Adverse events and concomitant medications were recorded		Recorded at each visit (Weeks 1, 3, 6, 9 and endpoint)